OBJECTIVES: Pharmacodynamics of HMR1426 in rodents. SUBJECTS: Male and female rats and male mice. MEASUREMENTS: 24 h feed consumption was measured. From the time curves IC 50 values of HMR1426 were calculated. Microanalysis of feeding behavior was determined. Macronutrient preference was measured, by offering rats three different diets. Gastric emptying was measured after liquid gastric loads or solid meals. In rats with gastric cannulas, milk consumption was measured with closed or open cannulas. Diabetes-related parameters and thyroid hormones were measured. RESULTS: HMR1426 inhibited feed consumption dose-dependently in rodents. Microstructural analysis of feeding after HMR1426 differed from central acting anorectics. HMR1426 inhibited consumption of fat-and carbohydrate-enriched diets. Gastric empyting was dose-and time-dependently delayed. Gastric emptying correlated with the time course of the anorectic effect. In sham-fed rats, HMR1426 had no anorectic effect with open cannulas. Anorectic effect occurred with closed cannulas. We proved that HMR1426 is not a CCK A agonist. CONCLUSION: The correlation between anorectic properties of HMR1426 and gastric emptying suggests that gastric emptying may cause the anorectic properties of HMR1426. The differences in microstructural feeding behavior between HMR1426 and centrally active anorectics makes it unlikely that HMR1426 acts via the CNS. Evidence for a peripheral mode of action is derived from sham-fed rats with open gastric fistula. When the milk fed was drained, HMR1426 was ineffective. HMR1426 is not a CCK A agonist. The molecular action of HMR1426 causing gastric emptying and its anorectic properties are under investigation.
Introduction
About 50% of adult human subjects in the USA have a body mass index (BMI) of Z27 kg/m 2 with an increasing prevalence of obesity. 1 The direct and indirect socio-economic costs of obesity in the USA, including its associated complications (type 2 diabetes, hyperlipidemia, hypertension and coronary heart disease), were estimated to be in the range of B100 billions US $ in 1998. 2 The very poor acceptance of public educational programs, recommending healthy nutrition, restriction of caloric intake and physical exercise, has been disappointing. Therefore, the need for pharmaceutical intervention to reduce elevated body weight and the associated health risks is now becoming accepted by physicians, patients and the regulatory authorities. Currently two drugs, Sibutramine 3, 4 and Orlistat . Both drugs may reduce body weight by 5-10% within 1 year. There is an urgent medical need for more efficacious drugs to treat obesity. Several new compounds with different modes of action are currently under development, the majority of them are still in preclinical development or in Phase I studies. [7] [8] [9] HMR1426 is a new chemical entity. Its chemical structure is shown in Figure 1 . Owing to its anorectic properties, the compound was thought to be a useful antiobesic agent. HMR1426 was tested in patients with BMI430 and those having a BMI427, with one or more comorbidities, according to the WHO recommendations. 10 The details of the study protocol and the amount of weight loss obtained in the patients of this study will be reported in a separate paper. In a previously reported animal study, we have shown a significant weight loss in obese Zucker fatty rats after administration of 50 mg/kg p.o. HMR1426, given for 2 weeks.
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Animal experiments were approved by the Department of Veterinary Affairs (Regierungspräsident, Darmstadt, Germany) and performed to Aventis Animal Health and Welfare guidelines. All animals were obtained from a commercial breeder; Harlan Winkelmann, Paderborn/Borchen, Germany. . HMR1426 was suspended in Tylose MH300 (1%) and given by gavage in a volume of 2 ml/kg (rat) or in Tylose HEC H400 (0.5%) 10 ml/kg (mice) p.o.
Methods and materials
GW5824 was suspended in Tylose HEC H4000 (0.5%) and given by gavage in a volume of 10 ml/kg (mice) p.o. Devazepide was dissolved in saline and given in a volume of 1 ml/kg (mice) subcutaneously (s.c.). Control animals always received equal volumes of the corresponding vehicle. Drug reference compounds were synthesized by Medicinal Chemistry, Aventis Pharma GmbH, Frankfurt-Main, Germany.
The studies presented in this article describe the preclinical, pharmacological background of HMR1426. The anorectic activity of this compound was tested in female and male Wistar rats, Sprague-Dawley rats and male NMRI mice under fasted and fed conditions. To gain insight into the anorectic mode of action of HMR1426, we tested the effects of the drug on gastric emptying in rats and in sham-fed rats with gastric cannula. In mice we tested the putative properties of HMR1426 as a CCK A agonist.
Measurement of feed consumption in rats and mice
Animals were placed individually in cages (Macrolon-cage (Type 4), size: 44 Â 26 Â 15 cm) equipped with a device for continuous monitoring of feed consumption. This device is a container, filled with feed and hanging on an electronic balance. The balance transmits the weight changes of the feed container continuously to a central unit, data were stored and processed at the end of the experiment. This system can measure feed consumption up to 3 weeks from 4100 feeding sensors simultaneously. The feeding monitoring system and data processing hard-and software (Release V3.07-03/2001) were obtained from TSE, Technical & Scientific Equipment GmbH, Bad Homburg, Germany. Software options: The data are processed from a matrix. The matrix delivers cumulatively or sequentially feed consumption in grams (g) for given time intervals for each individual animal. Cumulative and sequential feed consumption shown in tables, figures or in the text is normalized to g feed/time/100 g body weight (bw) in the rat experiments, if not otherwise stated.
A program for microstructural analysis calculates the parameters for feed consumption over a given time (24 h). Parameters delivered are: number of meals (Nm/time), intermeal breaks (IMB), (min), average meal size (g) and average meal duration (min). In the present study, a meal was defined to be Z0.5 g and the IMB Z15 min. Details of this method are described elsewhere. 12 
Housing conditions
The animals were kept on standardized conditions, temperature 22721C and relative humidity being 60710%. Night/ day rhythm: (0012-2400/2400-1200, next day), light intensity ¼ 250-300 lux/m 3 . All animals had free access to tap water and SSNIFFt pellets ssniff R/MH (1 g of feed ¼ 12.2 kJ) (Soest, Germany) during the experimental session. Before beginning the experiments, the animals were habituated for 2 days to the feeding monitoring cage.
Measurement of the anorectic potency
Cumulative feed consumption was measured to determine the anorectic potency of the drug under various conditions. Male and female animals of different species and strains under fed and fasted (18 h) conditions were used. ID 50 values were calculated from cumulative feed consumption 10 h after administration of HMR1426 and compared to the corresponding feed consumption at 10 h from controls. At least 3-4 doses with 8-16 animals per dose were used. The weight of the animals is given in Table 1 . The drug was given at time 0 min and the duration of the study was 24 h.
Microstructural analysis of 24 h feeding behavior
Fasted female Wistar rats with an initial body weight of 244715 g were used. Four to eight independent experiments Figure 1 Chemical structure of HMR1426.
HMR1426 a new anorectically active compound M Bickel et al were performed using 6-8 rats/group. Microstructural analysis of 24 h feeding behavior was characterized by the following parameters: meal frequency (n/24 h), IMB, (min), average meal size (g) and average meal duration (min). In the present study, a meal was defined to be Z0.5 g and the IMB Z15 min. The drug was given at time 0 min and the duration of the study was 24 h.
Macronutrient preference test
Fasted male Wistar rats with an initial body weight of 457732 g were used. Two independent experiments under identical conditions were performed using 16 rats/group. Monitoring of feed consumption and housing conditions was as described above. In addition to the method described above, the animals had free access to three different diets, each in a separate container hanging on individual electronic balances in each cage, thereby enabling the consumption of each of the diets to be monitored separately. The diets offered were all from SSNIFFt, Soest, Germany. The animals were habituated to being fed these three diets simultaneously for at least 2 weeks prior to the study. From the amount of feed consumed of each diet, the energy intake (kJ/ 24 h/100 g bw) was calculated. The drug was given at time 0 min and the duration of the study was 24 h.
Macronutrient and caloric composition of the diets applied per 100 g pellet are given in Table 2 .
Gastric emptying of a liquid noncaloric meal (phenol red method) Female Wistar rats weighing 225723 g were fasted for 18 h but had access to drinking water ad libitum. The animals had free access to water until 0.5 h before administration of the phenol red marker solution. In order to measure the timedependent effect of HMR1426 (60 mg/kg p.o.), the compound was administered at various times (0.5, 1, 3, 6, 9, 12, 15, 18, 22 and 24 h) before the application of the phenol red maker solution. After the administration of the marker solution (1.5 ml carboxymethlycellulose; phenol red solution. The marker solution consisted of carboxymethlycellulose (2%) and phenol red (0.7%) in saline. The initial phenol red concentration of 700 mg/ml was, due to the processing procedure, diluted to a final concentration of 4.8 mg/ml. 13, 14 per rat p.o.), animals were killed 15 min later and the stomach was removed. The stomach including its contents was homogenized in alkaline medium. Protein was precipitated with trichloroacetic acid. The homogenate was centrifuged and phenol red of the supernatant of the gastric phenol red concentration (GPRC), (mg/ml of processed homogenate) was measured colorimetrically at 546 nm (Spectrophotometer, LK Ultrospec II, Pharmacia, Upsalla, Sweden). The phenol red concentration measured in the homogenate of the stomach was a direct parameter of gastric emptying rate. The housing conditions were as described above.
Gastric emptying of a caloric solid meal Female, Wistar rats with an initial body weight of 224718 g were fasted for 18 h before beginning the study, but had free access to water throughout the experiment until termination of the feeding interval. Three rats were housed in one cage (Macrolon-cage (type 4), size: 44 Â 26 Â 15 cm). The animals had free access to SSNIFFt pellets ssniff R/MH (1 g of feed ¼ 12.2 kJ) (Soest, Germany) for 90 min. Then, the feed was removed and the amount of feed consumed by the animals was determined. Thereafter, HMR1426 (15, 30 and 60 mg/kg p.o.) or drug vehicle was administered. The animals were killed at various time intervals (0.5-24 h) after drug or drug vehicle treatment and the amount of feed remaining in the stomach was measured (the method we used was a slight modification of that described elsewhere. 15, 16 Sham-feeding in rats with chronically implanted gastric fistula Male, fasted Wistar rats with an initial bw of 452738 g were used. The animals were anaesthetized with Isoflurant and a mixture of O 2 /NO 2 (4/1; v/v). The abdominal wall was opened and a stainless steel cannula was inserted into the stomach. The cannula was closed with a screw to avoid leakage of gastric content under normal conditions. The peritoneum, the muscle layer and the skin were closed with interrupted sutures. 17 The animals were housed in individual cages. The housing conditions were, as described above. At 2 weeks after surgery, the animals are trained to be housed in cages, slightly restricting physical movements. During the experimental session, the rats are offered sugared milk (1 ml ¼ 3.27 kJ). The milk consumption was monitored for a duration of 5 h. Two experimental conditions were tested: (A) milk consumption with closed and (B) open cannula (sham-feeding). In the latter case, the amount of milk was measured, which was drained from the stomach through a catheter being connected to the cannula after removing the screw. The animals received 50 mg/kg p.o. HMR1426. After 1 h the milk was offered and the amount consumed was measured up to 5 h. In the experiment with open cannula (sham-feeding), the milk consumed and that drained from the stomach was measured at up to 5 h.
Measurement of milk consumption in mice (CCK A antagonist)
Male, fasted (24 h) NMRI mice with an initial body weight of 2774 g were placed individually in cages having free access to sugared milk (1 ml ¼ 3.27 kJ) in a graduated cylinder, to monitor the amount of milk consumed by the animals. Milk was offered at time 0 min. Cumulative milk consumption was measured at 2, 4 and 6 h after drug or vehicle administration. The experiments were performed during the light phase. The housing conditions were as described above. There were six groups (six mice/(group)) of mice treated as follows: (1) the controls received saline s.c., (À30 min), (2) GW5824 was suspended in Tylose HEC H4000 (0.5%) and given by gavage in a volume of 10 ml/kg (mice) p.o. Devazepide was dissolved in saline and given in a volume of 1 ml/kg (mice) s.c. Control animals always received equal volumes of the corresponding vehicle. Drug reference compounds were synthesized by Medicinal Chemistry, Aventis Pharma GmbH, Frankfurt-Main, Germany.
Oral glucose tolerance test and diabetes-and obesityrelated blood and serum parameters and thyroid hormone levels A total of 16 fasted, female Wistar rats (279723 g) were randomly distributed to the treatment groups, N ¼ 8/group. After an overnight fasting period, the animals received HMR1426 (60 mg/kg p.o.) or the solvent (Tylose MH300). After 1 h, the animals were given 2 g/kg glucose p.o. Blood was withdrawn from the tip of the tail, 15, 30, 60, 90, 120, 150, 180, 210 and 240 min later and blood glucose (Glucoquantt Boehringer, Mannheim, Germany) was measured.
After 1 week, HMR1426 (60 mg/kg p.o.) was given after an overnight fasting period (18 h). After 1 h the animals were anaesthetized and exsanguinated through the vena cava. The following parameters were measured in blood or serum: blood glucose (Gluco-quantt Boehringer, Mannheim, Germany), lactate in blood (MPR 2, lactate for use in sport medicine, Boehringer, Mannheim, Germany), serum insulin (Insulin, RIA (code 10624), Biochem. Immunosystems, Freiburg, Germany), cholesterol (CHOL (Cholesterin CHOP-PAP) Boehringer, Mannheim, Germany), triglycerides (Triglyceride GPO-PAP Boehringer, Mannheim, Germany), free fatty acids (FFA) (NEFA C, enzymatic color test for unesterified fatty acid in serum or plasma, Wako Chemicals GmbH, Neuss, Germany), thyroid stimulating hormone (TSH) (TSH-RIA, Worksheet, Lab. Prof. Sandow, Aventis Pharma Deutschland GmbH, Metabolic Diseases, Germany), triiodothyronine (T3) (Coat-A-Countt, total T3, DPC, Diagnostic Products Corporation, Los Angeles, CA 90045-5597, USA) and thyroxine (T4) (Coat-A-Countt, total T4, DPC, Diagnostic Products Corporation, Los Angeles, CA 90045-5597, USA).
HMR1426 was suspended in Tylose MH300 (1%) and given by gavage in a volume of 2 ml/kg.
Data evaluation and statistics
All parameters were tested for normal distribution and homogeneity of variances. Significant differences between variables were calculated using parametric procedures. If one of the above-mentioned criteria was not fulfilled, nonparametric procedures were employed. Dose-response relationships were calculated by simple analysis of linear regression, using the feed consumption 10 h after drug administration, after log transformation of the abscissa values: (Figure 2 ).
In female, fed Wistar control rats feed consumption was 7.970.6 g/100 g (24 h) bw. In the first 12 h (night time), the animals consumed 6.471.3 g/100 g bw, representing 81% of the total feed eaten. HMR1426 inhibited cumulative feed consumption in female, fed Wistar rats in a dose-dependent fashion (3, 10 and 30 mg/kg p.o.). Analysis of regression revealed: Y (5.64 g/100 g bw/10 h) ¼ 7.42-(3.87 log Â (mg/kg)) (Po0.001). ID 50 ¼ 1572 mg/kg p.o. The duration of action after dosing of 30 mg/kg p.o. lasted for 24 h (Figure 3 ). The corresponding dose-response curves on the inhibitory effect of HMR1426 in fasted and fed, female Wistar rats are shown in Figure 4 .
The 24 h feed consumption in male, fasted Wistar control rats was 9.270.9 g/100 g bw. In the first 12 h (night time), the animals consumed 7.771.1 g/100 g bw, representing 84% of the total feed consumed.
HMR1426 inhibited cumulative feed consumption in male, fasted Wistar rats in a dose-dependent fashion (3, 10, 30 and 100 mg/kg p.o.). Analysis of regression revealed: Y (7.16 g/100 g bw/10 h) ¼ 7.86À(3.08 log Â (mg/kg)) (Po0.001). ID 50 ¼ 2472 mg/kg p.o. The duration of action after dosing of 30 and 100 mg/kg p.o. lasted for 24 h.
In male, fed Wistar control rats feed consumption was 8.171.4 g/100 g (24 h) bw. In the first 12 h (night time), the animals consumed 4.471.3 g/100 g bw, representing 55% of In female, fed rats SPGD, control feed consumption was 7.971.1 g/100 g bw (24 h). In the first 12 h (night time), the animals consumed 5.371.2 g/100 g bw, representing 67% of the total feed eaten in 24 h. HMR1426 inhibited feed consumption in female, fed SPGD rats in a dose-dependent fashion ( In male, fasted rats SPGD, control feed consumption was 10.271.7 g/100 g bw (24 h). In the first 12 h (night time), the animals consumed 8.370.9 g/100 g bw, representing 81% of the total feed eaten in 24 h. HMR1426 inhibited feed consumption in male, fasted SPGD rats in a dose-dependent fashion (5, 15 and 45 mg/kg p.o.). Analysis of regression revealed: Y (7.91 g/100 g bw/10 h) ¼ 8.53À(2.59 log Â (mg/ kg)) (Po0.01), ID 50 ¼ 58720 mg/kg p.o. The duration of action after dosing of 15 and 45 mg/kg p.o. lasted for 24 h.
In male, fed rats SPGD, control feed consumption 7.870.8 g/100 g bw (24 h). In the first 12 h (night time), the animals consumed 6.370.6 g/100 g bw, representing 80% of the total feed eaten in 24 h. HMR1426 inhibited feed consumption in male, fed SPGD rats in a dose-dependent fashion ( In male, fasted NMRI mice, control feed consumption in was 2477.0 g/100 g bw (24 h). In the first 12 h (night time), the animals consumed 1877.2 g/100 g bw, representing 74% of the total feed eaten in 24 h. HMR1426 inhibited feed consumption in male, fasted NMRI mice in a dose-dependent fashion (3, 10 and 30 mg/kg p.o.). Analysis of regression revealed: Y (14.7 g/100 g bw/10 h) ¼ 15.6À(5.34 log Â (mg/ kg)) (Po0.01) ID 50 ¼ 35713 mg/kg p.o. The duration of action after dosing of 30 mg/kg p.o. lasted o24 h.
In male, fed NMRI mice, control feed consumption was 1875.4 g/100 g bw (24 h). In the first 12 h (night time), the animals consumed 1475.5 g/100 g bw, representing 77% of the total feed eaten in 24 h. HMR1426 inhibited feed consumption in male, fed NMRI mice in a dose-dependent fashion ( Body weight, number of animals used in each experiment and all ID 50 values are summarized in Table 1 .
Microstructural analysis of 24 h feeding behavior
The 24 h feed consumption in female, fasted Wistar control rats was 20.272.4 g/rat, which is in excellent accordance with the value from the experiment shown in Figure 2 . In this experiment 24 h feed consumption was 19.971.8 g/rat. Fasted female Wistar control rats had 13.970.95 meals in 24 h with IMB of 90.270.6 min. Meal duration was 5.6871.23 min with a meal size of 1.4570.14 g/rat. Total feeding time was 79.2720 min, or 5.4% of the 24 h experimental session.
HMR1426 at a dose of 50 mg/kg p.o. extensively reduced the number of meals by 59% and consequently increased IMB by 183%. Meal duration as well as meal size were not affected. Total feeding time was reduced by 57% and inhibition of total feed consumption was 53% after application of 50 mg/kg p.o. HMR1426. We conclude that the inhibition of total 24 h feed consumption is exclusively caused by the inhibitory effects of HMR1426 on meal frequency (Table 3) .
Macronutrient preference test
Female, fasted Wistar control rats having access to three different diets simultaneously consumed during the 24 h experimental session 5974 kJ of the fat-rich diet (FRD), 
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3076 kJ of the carbohydrate-rich diet (CHRD) and 1574 kJ of the standard diet (STD), which corresponds to a total energy consumption of 10474 kJ/24 h. Under these conditions control rats preferred FRD, followed by CHRD and finally STD. The ratio between the diets consumed was FRD ¼ 4/CHRD ¼ 2/STD ¼ 1 in control animals. HMR1426 (50 mg/kg p.o.) significantly inhibited preference for FRD by 73% and preference for carbohydrate rich diet by 33%. Owing to the preference change, the animals receiving HMR1426 consumed 46% more of the STD, although this diet was the least appetizing when offered to controls (Table 4) .
Sequential feeding and gastric emptying rate of a liquid noncaloric meal Female, fasted Wistar control rats consumed a total of 9.9 g/ 100 g bw during 24 h. In the first 12 h of the experiment, 8.1 g/100 g, 82%, of the total feed was consumed. This confirms the results from the experiment shown in Figure 2 , where fasted rats consume B80% of their 24 h total feed during the dark phase, which is the activity phase in rats. HMR1426 (60 mg/kg p.o.) significantly inhibited sequential feed consumption, starting 1-2 h after drug administration. Inhibition reached a maximum (98%) after 6 h. Inhibition was maintained at a plateau until 18 h with an average inhibition of 7879%, and decreased continuously until the end of the experiment (Table 5) .
GPRC in female, fasted control Wistar rats given drug vehicle at different times prior to the phenol red marker was 0.3870.11 mg/ml (0.5-24 h). Administration of HMR1426 (60 mg/kg p.o.) given 0.5-24 h prior to the marker, caused an increase of GPRC up to 1.7970.34 mg/ml within 6 h, remained elevated until 18 h. Thereafter, GPRC declined continuously to control values within 24 h (Table 6 ). The time course of inhibition of sequential feed consumption and GPRC were parallel ( Figure 5 ). When plotting the inhibition of sequential feed consumption against the time corresponding GPRC after treatment with HMR1426, a highly significant correlation, R ¼ 0.855, df ¼ 10, Po0.001, could be demonstrated (Table 6; Figure 6 ).
Gastric emptying rate of a caloric solid meal Female, starved Wistar rats consumed 3.172.0 g/ 100 g bw ¼ 38724 kJ g/100 g bw during the 90 min feeding period. Immediately thereafter, at zero time, 2.870.6 g/ 100 g bw (90% of feed eaten was detected in the stomach). Rats were killed at increasing times until 24 h. The amount of feed recovered from the stomach was plotted against time (h). All values of vehicle-treated animals, and those given increasing doses of the drug, fitted to negative exponential functions. After ln-transformation of the feed recovered from the stomach, straight lines were obtained and the half life time of gastric emptying of solid feed was calculated by the (Table 7 ; Figure 7 ).
Sham feeding in rats
Cannula closed. Fasted, male Wistar control rats consumed 33.873. 7 ml milk/5 h/rat. HMR1426 (50 mg/kg p.o., applied 1 h before offering the milk) consumed only 11.673.1 ml milk/5 h/rat, which is significantly less (À66%; Po0.001) compared to the controls. Freely moving rats with closed gastric cannula (kept in their normal home cages) consumed 31.372.5 ml milk/5 h/rat; N ¼ 8, after treatment with HMR1426 (50 mg/kg p.o. (N ¼ 8), 1 h before offering the milk, the rats consumed 11.171,1 ml milk/5 h/rat, which is significantly less (À64%; Po0.001) compared to controls. This documents that the mild physical restriction of the rats with the cannula did not affect milk consumption and does not influence the inhibitory effect of HMR1426. The time course of gastric emptying as shown in Figure 7 fitted to a negative exponential function. Y ðgÞ ¼ a o Ã e a 1 t . Half life of gastric empyting T 1/2 (h) ¼ ln 2/a 1 is shown as means7s.e.m., a 1 being the slope of the regression lines and r being the coefficient of regression. 
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Cannula open. Under these conditions, fasted, male Wistar control rats consumed 64.576 ml milk/5 h/rat, which is B90% more than under the conditions with closed cannula. HMR1426 (50 mg/kg p.o.) applied 1 h before offering the milk had no significant effect on milk consumption (À10%). The volume of milk drained, in the controls as well as in the drug-treated rats, was slightly higher (control ¼ þ 6% and after HMR1426 ¼ þ 13%). This slightly higher volume drained from the stomach might be due to some gastric secretions and derive also in part from secretions from the salivary glands, which is swallowed during the experimental session (Table 8) .
Milk consumption in NMRI mice after application of a CCK A antagonist In control mice, cumulative milk consumption was 1.0870. 87 (2 h), 2.3171.19 (4 h) and 3.2771.24 ml/mouse after 6 h (N ¼ 6). HMR1426 (50 mg/kg p.o.) significantly inhibited cumulative milk consumption by 93%, (2 h), 90% (4 h) and 80% after 6 h. The CCK A agonist GW5824 (10 mg/kg) also showed strong anorectic activity, cumulative milk consumption was inhibited by 96% (2 h), 98% (4 h) and 94% after 6 h. The CCK A antagonist devazepide (30 mg/kg s.c.) alone had no effect on milk consumption in mice; however, the anorectic activity of GW5824 was completely abolished when given together with devazepide. However, devazepide given together with HMR1426 did not antagonise the anorectic activity of HMR1426 (Figure 8 ).
Oral glucose tolerance test and diabetes-and obesityrelated blood or serum parameters and thyroid hormone levels In the oral glucose tolerance test (2 g/kg p.o. ) in rats, HMR1426 (60 mg/kg p.o.) did not lowered glucose levels. In contrast, the compound caused a significant elevation of glucose concentrations in the descending part of the glucose kinetics from 150 to 240 min ( Figure 9 ). Basal blood glucose and blood lactate, cholesterol, triglycerides, free fatty acids and the thyroid hormones (TSH, T3 and T4) were not influenced by treatment with 60 mg/kg p.o. HMR1426 in female Wistar rats. Serum insulin was significantly elevated ( Table 9 ).
Discussion
The 24 h feed consumption in female and male, fasted and fed control rats was constant with a relative coefficient of variability, CV o 3%, indicating a very low intraindividual variability of feed consumption. HMR1426 inhibited feed consumption and delayed gastric emptying rate. The close correlation in the time course (Po0.001) of the anorectic effect and the inhibition of gastric emptying in the present study suggests that the anorectic activity of HMR1426 might be predominantly due to an inhibition of gastric emptying, also this correlation might, of course, be coincidental.
HMR1426 enforces satiety, rather than suppressing hunger. This is concluded from the fact that fed animals (preloaded stomach) are more sensitive to the anorectic effect of HMR1426 than fasted animals. Feed consumption measured over a period of 24 h revealed that HMR 1426 inhibited feed intake in rats of different strains (Wistar and Sprague Dawley), males and females, in male NMRI mice, and under different nutritional states (18 h fasted and fed animals). In all experiments HMR1426 inhibited 24 h cumulative feed In both rat strains tested as well as in mice regardless of gender of the animals, the fed animals were always more sensitive to the anorectic effect of HMR1426 than the fasted ones. The average anorectic potency ratio of HMR1426 in fed animals was significantly higher (2.770.8 times; Po0.01) than in fasted animals, independent of sex or species.
In 18 h fasted rats, the stomach is nearly empty, whereas fed rats have feed remaining in their stomach from the previous feeding period. The fact that HMR1426 on a preloaded stomach had a more pronounced anorectic effect suggests that gastric distension may play an important role in its anorectic effect. Microstructural analysis of 24 h feeding patterns showed that the number of meals consumed by rats treated with HMR1426 was reduced by 59%. Consequently, the duration of IMB was raised by 183%. No significant effect of HMR1426 on meal size or meal duration could be detected. Thus, the inhibition of total feed intake was related to the reduction in the number of meals taken by the animals. These observations suggest that HMR1426 enforces satiety, which again is support the observation that fed animals with a preloaded stomach react more sensitive to the anorectic effect of HMR1426. The microstructural profile of HMR1426 differs significantly from that seen with several centrally acting drugs (amphetamine, dexfenfluramine and sibutramine involved in norepinephrine or serotonin release and/or inhibition of reuptake of these monoamines). 12, 19 In the feed preference test HMR1426 (50 mg/kg p.o.) significantly reduced the consumption of the FRD and the CRD. In contrast, the drug-treated rats consumed more of the SD, although this diet was less appetizing to control rats. In rats with chronically implanted gastric cannulas, animals with closed gastric cannulas showed the expected anorectic efficacy of HMR1426, as seen in the numerous previous experiments. However, when HMR1426 was given to rats with open cannula (sham-feeding), which allows the milk consumed to be drained from the stomach, no anorectic effect of HMR1426 could be detected at all. The missing anorectic effect of HMR1426, in sham-fed rats, prove that that there is no role for a central nervous system derived anorectic signal to explain the anorectic effect of HMR1426 and strongly suggests that the anorectic effects are of peripheral origin, whereby the gastropyloric region plays an important role.
This observation is in line with binding studies, investigating HMR1426 (up to 10 À5 M), with monoamine (serotonine, norepinephrine and dopamine) receptors and their known subtypes, transporters and reuptake mechanisms involved in feeding regulation. In none of these assays any significant binding could be detected. Also no binding to numerous brain/gut peptide receptors could be detected: angiotensin II: A T1 , A T2 , bombesin, calcitonine gene-related protein, CCK A/B , galanin: GAL 1/2 , glucagon like peptide-1, leptin, motilin, neuropeptide Y: NPY 1/2 , neurotensin, somatostatin and vasointestinal polypeptide (VIP). 20 The GI-hormone cholecystokinin (CCK) has, in addition to its effects on gallbladder contraction and on pancreatic enzyme secretion, two properties that are also observed with HMR1426: CCK inhibits gastric emptying and has a short lasting anorectic activity. 21, 22 Since the discovery of two subtypes of CCK receptors, CCK A receptors predominantly located in the periphery and the CCK B receptor located in the CNS, 23 numerous nonpeptidergic CCK A agonists have been synthesized and have been shown to mimic all properties of CCK. [24] [25] [26] We therefore tested whether HMR1426 was acting as a CCK A agonist. The CCK A agonist GW5824 inhibited cumulative milk consumption in mice after 2, 4 and 6 h on an average by 98%. This anorectic effect was completely prevented by simultaneous application of the CCK A -antagonist devazepide. In NMRI mice, HMR1426 inhibited cumulative milk consumption after 2, 4 and 6 h on an average by 90%. In the presence of the CCK A -antagonist devazepide, inhibition of cumulative milk consumption by HMR1426 was not affected.
In an oral glucose tolerance test (2 g/kg p.o.) in rats, HMR1426 did not lowered glucose levels. In contrast, the compound caused a significant elevation of glucose concentrations in the descending part of the glucose kinetics. This observation could be explained by the long lasting and powerful inhibitory effect of HMR1426 on gastric emptying rate, with a delay in the delivery of glucose into the duodenum.
Acute treatment with HMR1426 had no effects on diabetes-and obesity-related parameters in female Wistar rats, except a significant increase in serum insulin. Thyroid hormones were not affected. This makes it unlikely that HMR1426 effects energy expenditure, which was confirmed by direct measurements of energy expenditure after treatment with HMR1426 in rats. 24 
HMR1426 a new anorectically active compound M Bickel et al
There is no evidence that the specific pharamcodynamic effect (inhibition of feed intake, under a large variety of conditions and the inhibitory effects of HMR1426 on gastric emptying rate are caused by a general toxic effect of this compound. In acute experiments in guinea-pigs (50 mg/kg p.o.), pigs (150 mg/kg p.o.), and monkeys (300 mg/kg p.o.) HMR1426, no signs of sickness behavior or vomiting was observed. In a 3 month toxicological studies in male and female Wistar rats, no pathological changes in routine serum analytes or histological examinations were observed at a dose of 1000 mg/kg p.o. This is clearly in contradiction with the assumption that the pharmacodynamic effects of HMR1456 (gastric emptying rate and anorectic activity) are of ''toxic'' origin. The anorectically active ID 50 values for male and female Wistar rats were 1072 and 19710 mg/kg p.o., and thereby 100-50 times less than the dose tested in the 3-month toxicological study (unpublished data).
Future studies will now focus on our studies to elucidate the molecular mode of action of HMR1426. However, there is a finite set of peripherally active satiogens known to affect food intake and gastric emptying (amylin, GLP1, urocortin, secretin, bombesin, PYY, neuromedin-U). If one of these peptides should be involved in the mode of action of HMR1426, it will complicate the question whether gastric emptying is the cause of the anorectic activity of HMR1426, or whether these two properties of HMR1426 are independent of each other.
